Radius Health (RDUS) Misses Q4 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Radius Health Reports Fourth Quarter and Full Year 2015 Financial and Operating Results
February 25, 2016 6:30 AM ESTManagement to host conference call today at 7:30 am ET.Radius submitted an MAA in Europe for the investigational drug abaloparatide-SC for the potential treatment of postmenopausal osteoporosis and reduction of fracture risk on November 17, 2015. The application has been validated by the EMA and is currently under regulatory review. Radius is on track to submit an NDA for abaloparatide-SC in the U.S. at the end of the first quarter of 2016.
WALTHAM, Mass., Feb. 25, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Radius or the Company) (Nasdaq:... More
